

Joseph Therriault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6140777/publications.pdf>

Version: 2024-02-01

57
papers

2,944
citations

257101

24
h-index

233125

45
g-index

65
all docs

65
docs citations

65
times ranked

2932
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	2.7	65
2	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	2.7	34
3	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. Neuropsychopharmacology, 2022, 47, 1128-1136.	2.8	30
4	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	5.3	73
5	Staging of Alzheimer's disease: past, present, and future perspectives. Trends in Molecular Medicine, 2022, 28, 726-741.	3.5	36
6	APOE ϵ 4 potentiates the relationship between amyloid- β 2 and tau pathologies. Molecular Psychiatry, 2021, 26, 5977-5988.	4.1	51
7	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
8	Determining Amyloid- β 2 Positivity Using 18 F-AZD4694 PET Imaging. Journal of Nuclear Medicine, 2021, 62, 247-252.	2.8	65
9	Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada. Canadian Journal of Neurological Sciences, 2021, 48, 312-320.	0.3	0
10	Topographic Distribution of Amyloid- β 2, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. Neurology, 2021, 96, e81-e92.	1.5	31
11	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 1.	3.6	23
12	Apolipoprotein E ϵ 4 and ϵ 3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid- β in mild cognitive impairment but not in Alzheimer's disease. Journal of Integrative Neuroscience, 2021, 20, 277.	0.8	2
13	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12154.	1.8	19
14	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 69.	3.0	34
15	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	1.5	15
16	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. Molecular Neurodegeneration, 2021, 16, 28.	4.4	32
17	The Effects of CSF Neurogranin and APOE ϵ 4 on Cognition and Neuropathology in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 667899.	1.7	6
18	Interactive rather than independent effect of APOE and sex potentiates tau deposition in women. Brain Communications, 2021, 3, fcab126.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	1.5	33
20	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
21	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 97, 609-609.	1.5	2
22	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	3.7	47
23	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 96, e975-e985.	1.5	42
24	Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2083-2092.	1.7	7
25	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
26	The Role of Apolipoprotein E ϵ 4 in Early and Late Mild Cognitive Impairment. <i>European Neurology</i> , 2021, 84, 472-480.	0.6	3
27	Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease. <i>Journal of Integrative Neuroscience</i> , 2021, 20, 861-870.	0.8	10
28	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	1.3	4
29	Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β . <i>JAMA Neurology</i> , 2020, 77, 470.	4.5	154
30	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	3.7	147
31	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	3.7	60
32	Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1211-1213.	1.4	5
33	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 334-348.	0.7	34
34	Frontal tau pathology underlies behavioural / dysexecutive clinical presentations of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043947.	0.4	0
35	Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044897.	0.4	2
36	Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046191.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.4	102
38	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
39	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 288-293.	0.5	6
40	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid β -positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	1.2	48
41	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum. <i>Molecular Neurobiology</i> , 2019, 56, 8336-8344.	1.9	6
42	$\text{A}\beta$ -induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	5.8	58
43	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102091.	1.4	21
44	Mind-Body Interventions in Late-Life Mental Illnesses and Cognitive Disorders: A Narrative Review. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 536-547.	0.6	7
45	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018, 90, e932-e939.	1.5	54
46	O3a β 01a β 04: CORRELATION BETWEEN CSF T β CTAU AND P β CTAU WITH [¹⁸ F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1009.	0.4	0
47	P2a β 62: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXEL-WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P898.	0.4	0
48	ICa β Pa β 022: LATERAL TEMPORAL AMYLOID LOAD PREDICTS PROGRESSION TO ALZHEIMER'S DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P28.	0.4	0
49	ICa β Pa β 023: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXEL-WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P29.	0.4	0
50	P1a β 486: LATERAL TEMPORAL AMYLOID LOAD PREDICTS THE PROGRESSION TO ALZHEIMER'S DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P513.	0.4	0
51	In vivo quantification of neurofibrillary tangles with [18F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	3.0	120
52	Tai Chi Interventions in Mental Illness: Results From a Pilot Study in Adults and a Systematic Review in Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, S100-S101.	0.6	1
53	[ICa β Pa β 149]: LACK OF SELF-AWARENESS OF COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE IS RELATED TO DECREASED METABOLISM IN THE POSTERIOR CINGULATE CORTEX. <i>Alzheimer's and Dementia</i> , 2017, 13, P112.	0.4	0
54	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 25.	3.0	285

#	ARTICLE	IF	CITATIONS
55	[P2â€“476]: LACK OF SELFâ€“AWARENESS OF COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE IS RELATED TO DECREASED METABOLISM IN THE POSTERIOR CINGULATE CORTEX. Alzheimer's and Dementia, 2017, 13, P822.	0.4	0
56	[ICâ€“Pâ€“148]: LACK OF SELFâ€“AWARENESS OF COGNITIVE DEFICITS PREDICTS METABOLIC DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P112.	0.4	0
57	[P1â€“368]: LACK OF SELFâ€“AWARENESS OF COGNITIVE DEFICITS PREDICTS DEFAULT MODE NETWORK METABOLIC DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P401.	0.4	0